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ABO-incompatible kidney transplantation (ABOi KT) was introduced to expand the
donor pool and minimize shortage of kidneys for transplantation. Because improved
outcomes of ABOi KT were reported in Japan in the early 2000s, the number of ABOi KTs
has been increasing worldwide. In addition, a better understanding of immune
pathogenesis and subsequent aggressive immunosuppression has helped to make
effective desensitization protocols. Current strategies of ABOi KT consist of pretransplant
antibody removal using plasmapheresis or immunoadsorption to prevent hyperacute
rejection and potent maintenance immunosuppression, such as tacrolimus and myco-
phenolate mofetil, to inhibit antibody-mediated rejection. Recent outcomes of ABOi KT
are comparable with ABO-compatible KT. However, there are still many problems to be
resolved. Very high anti-ABO antibody producers are difﬁcult to desensitize. In addition,
ABOi KT is associated with an increased risk of infection and possibly malignancy due to
aggressive immunosuppression. Optimization of desensitization and patient-tailored
immunosuppression protocols are needed to achieve better outcomes of ABOi KT. This
review provides an overview of the history, immune mechanism, immunosuppressive
protocol, outcomes, current obstacles, and future perspectives in ABOi KT.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Kidney transplantation (KT) is the treatment of choice for
patients with end-stage renal disease. Unfortunately, the
number of end-stage renal disease patients on waiting lists is
increasing while the number of available kidneys is static. As a
result, the waiting time for KT continues to be very long. To
overcome the shortage of organs, various strategies have been
tried. Although xenotransplantation using pig organs and dif-
ferentiation to new organs using stem cell technology have
been studied, their clinical application is far from being realized.




eoul 110-744, Korea.overcome immunologic barriers such as anti-human leukocyte
antigen (HLA) donor-speciﬁc antibody (DSA) and ABO blood
group incompatibility.
ABO-incompatible living-donor KT (ABOi KT) is another
strategy to expand the organ pool and decrease the long
waiting times for deceased-donor KT [1,2]. After Alexandre
et al [3] introduced an effective desensitization protocol based
on plasmapheresis and splenectomy to prevent hyperacute
rejection across the ABO antibody barrier in 1987, ABOi KT has
been actively studied in Japan because of the lack of deceased
donors [4]. Although outcomes were not satisfactory before
2000, they improved signiﬁcantly after the introduction of
tacrolimus and mycophenolate mofetil (MMF) around 2000 [5].
When 5-year graft survival rates of ABOi KT in Japan were
analyzed according to the three eras (1989–1994, 1995–2000,
and 2001–2006), they were 68%, 76%, and 90%, respectively [6].
Outcomes of ABOi KT between 2002 and 2008 in Japan were
further improved after the introduction of rituximab, based onhrology. Published by Elsevier. This is an open access article under the
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survival rates of ABO-compatible (ABOc) KT, ABOi KT using
splenectomy, and ABOi KT using rituximab were 88.4%, 90.3%,
and 100%, respectively [8]. Currently, ABOi KT reached approxi-
mately 30% of all living-donor KTs in Japan [4].
Based on the successful outcomes of ABOi KTs in Japan, this
technique has been increasingly performed in the United
States and Europe since the late 1990s [9,10]. Although only
738 cases (0.94%) of ABOi KTs were performed between 1995
and 2010 in the United States, this number has been increasing
annually [11]. The same trend was observed in the United
Kingdom where, over the last decade, there has been an
increase of ABOi KT fromo10 to 73 per year, now representing
6.8% of all living-donor KTs [12]. After Tyden et al [7,10]
reported successful antibody reduction using ABO antigen-
speciﬁc immunoadsorption (IA), greater numbers of ABOi KTs
were performed in Europe. Although ABOi KT was introduced
relatively late in Korea, the numbers of patients and partici-
pating centers have expanded rapidly, and ABOi KT accounted
for 10% and420% of all living-donor KTs in Korea in 2010 and
2014, respectively [13,14].
To understand the current status and future perspectives of
ABOi KT, the present review focuses on immune mechanisms
including accommodation and antibody-mediated rejection
(AMR), immunosuppressive regimens, pretransplant and post-
transplant immune monitoring, outcomes, and unsolved pro-
blems of ABOi KT.Blood group antigens and antibodies
ABO blood group antigens
Blood group antigens are polysaccharides, do not require
T-cell sensitization for antibody induction, and induce poor
T cell-speciﬁc responses [15]. The most important blood
antigens consist of A, B, and O group antigens. These antigens
are found in many cells, including erythrocytes, platelets, and
endothelial cells of all vascular organs. ABO blood group
incompatibility is a signiﬁcant immunologic barrier because
humans have natural antibodies against the A and/or B
antigens that they do not have.
Blood group A carries A1 or A2 antigen, with expression of
A2 antigen weaker than that of A1 antigen [16]. The A2
subtype represents approximately 20% of blood type A in
Caucasians, whereas it is only 0.15% in the Japanese population
[17]. A2 kidneys may be less likely to undergo AMR in the
presence of anti-A antibodies. Non-A recipients receiving
kidneys from A2 donors can safely accept transplantation
without preconditioning.
Anti-ABO antibodies
Antibodies against the blood group antigens A and B are
isohemagglutinins because they react with A antigen and B
antigen in red blood cells and induce agglutination. Anti-ABO
antibodies are either immunoglobulin (Ig) M (IgM) or IgG
type. These antibodies are made during the development of the
immune system against cross-reactive epitopes on the cell wall of
gut bacteria, and their titer increases with age [18,19].
Anti-ABO antibodies are produced mainly by extrafollicular B-1
cells [20], in contrast to antipeptide antibodies that are produced
by follicular B-2 cells. However, the main anti-ABO-speciﬁc B-cellpopulations are not yet established. On the other hand, the anti-
ABO response is classically regarded as a T cell-independent IgM
antibody response; however, recent studies suggested a role for
natural killer cells or T cells in the anti-ABO antibody response [21]
and demonstrated that anti-ABO IgG response was more impor-
tant than the IgM response in AMR after ABOi KT [22]. Therefore,
the role of helper T cells in the anti-ABO antibody response should
be deﬁned.
Monitoring techniques
Monitoring of anti-ABO antibody levels is important for
determining the effectiveness of desensitization and the opti-
mal time to perform ABOi KT. In addition, the titer of anti-ABO
antibodies should be monitored after transplantation to detect
any rebound in antibody production, which may indicate or
induce AMR.
There are various methods to measure the anti-ABO anti-
body titer. The most common is the saline tube technique,
although there is signiﬁcant intercenter variation in the titer
determined by this method [23]. New techniques, such as gel
card technique and ﬂow cytometry, may be better than the
saline tube test because both show improved reproducibility
[23–27]. Flow cytometry would be suitable for an accurate
measurement but is not available at all centers because of its
high cost [27].Rejection and accommodation in ABOi KT
Antibody-mediated rejection
AMR is clinically suspected when the serum creatinine level
is elevated relative to the baseline value. Natural and induced
anti-ABO antibodies might cause AMR in ABOi KT and can
manifest as hyperacute rejection, acute AMR, or delayed AMR
[28]. After a silent period during the ﬁrst 2 days, most AMRs
occur between 1 week and 3 weeks after ABOi KT. Anti-ABO
antibodies usually do not induce AMR after 3 weeks despite a
titer rebound due to accommodation [28].
AMR after ABOi KT is diagnosed on the basis of morpholo-
gic, immunohistologic, and serologic evidences, with at least
one ﬁnding in each of the three categories [29–31]. Morpho-
logic features include leukocyte inﬁltration into peritubular
capillaries and/or glomeruli, arterial ﬁbrinoid necrosis, glo-
merular and arterial thrombi, and acute tubular injury. Immu-
nohistologic features involve peritubular capillary C4d
deposition and deposition of immunoglobulin and/or comple-
ment in arterial ﬁbrinoid necrosis. Circulating DSAs at the time
of biopsy should be found. However, deposition of C4d,
without other evidence of AMR in biopsy, was observed in
60–80% of ABOi KT patients [32–35]. A protocol biopsy
study demonstrated no differences in the incidence of either
AMR or transplant glomerulopathy according to C4d positivity
[34]. Moreover, graft function was stable despite the presence
of anti-ABO antibodies [31]. Therefore, the presence of anti-
ABO antibodies or the presence of peritubular capillary C4d
deposition alone is not diagnostic of AMR with ABOi KT
[36,37]. C4d deposition without other evidence of AMR
might indicate accommodation instead of AMR because the
presence of this feature in 3-month protocol biopsies was
associated with fewer chronic injuries than in 1-year protocol
biopsies [32].
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The resistance of an allograft to AMR, despite the presence
of signiﬁcant levels of anti-ABO antibodies and C4d deposition,
is known as accommodation. Accommodation differs from
tolerance which lacks DSA or anti-ABO antibodies. Accommo-
dation in xenotransplantation is transient and accompanied by
acute vascular or cellular rejection [38]. However, durable
accommodation is observed in many ABOi KT patients. Several
preliminary studies have examined the mechanisms leading to
accommodation. These include changes in the function of DSA,
changes in the antigen, acquired resistance of the allograft
through the expression of antiapoptotic genes such as heme
oxygenase-1, A20, bcl-2, and bcl-xL; expression of complement
regulatory proteins such as CD45, CD55, and CD59; and inactiva-
tion of extracellular-signal-regulated kinase-1/2 [39–43]. A small
microarray study suggested roles for SMAD, protein tyrosine
kinase, tumor necrosis factor-α, and mucin 1 in accommodation
[1]. Overall, further studies are needed to elucidate the mechan-
isms of accommodation and to develop noninvasive diagnostic
tools of accommodation for patient-tailored immunosuppressive
therapy.Desensitization for ABOi KT
Current immunosuppressive strategies for ABOi KT have
two main principles: (1) pretransplant antibody removal and
(2) induction and maintenance of immunosuppression to
inhibit the reappearance of anti-ABO antibodies.
Antibody depletion
Antibody-depleting treatment is the basis of desensitization for
ABOi KT. Current methods for the removal of anti-ABO antibodies
involve classical plasmapheresis, double-ﬁltration plasmapheresis
(DFPP), and antigen-speciﬁc or antigen-nonspeciﬁc IA.
Classical plasmapheresis completely removes all plasma
proteins from the circulation, and the recipient plasma is
replaced by either albumin, fresh-frozen plasma (FFP), or a
combination of both. Owing to the removal of coagulation
factors and useful immunoglobulins, the risk of bleeding and
infections is increased after plasmapheresis. To avoid these
complications, many centers use FFP for the ﬁnal sessions
before transplantation. Other complications were hypocalce-
mia, hypotension, and nausea or vomiting [44].
For DFPP, plasma is separated by ﬁltration and passed
through a second ﬁlter where immunoglobulins are selectively
ﬁltered out and discarded. DFPP can minimize hemodynamic
instability and the amount of replacement volume needed. DFPP
also removes 60–70% of the antibodies per session. This is
greater efﬁciency than classical plasmapheresis that removes
only 40–50% [45]. Although DFPP avoids the loss of coagulation
factors and albumin, unlike classical plasmapheresis, albumin is
almost always needed in the replacement ﬂuid.
IA can remove antigen-speciﬁc antibodies, such as anti-ABO
antibodies, or antigen-nonspeciﬁc immunoglobulins. Between
the speciﬁc and nonspeciﬁc IA techniques, antigen-speciﬁc IA
is used more commonly in ABOi KT, whereas antigen-
nonspeciﬁc IA is suitable for the depletion of anti-HLA anti-
bodies. In ABO-speciﬁc IA, the plasma is processed through an
ABO immunoadsorbent column that is coated with either
blood type A or B antigens. This allows the selective removalof anti-A or anti-B antibodies, and the processed plasma is
then reinfused into the recipients. Antigen-speciﬁc IA removes
a twofold to fourfold titer per session. At least four preopera-
tive IAs are usually needed to obtain an acceptable titer [46]. IA
is normally preferred because of its safety and efﬁcacy. How-
ever, the application of IA outside Europe and Australia is
limited because of its high cost that is often not covered by
health insurance.
Posttransplant antibody depletion is used routinely in some
centers with a variable number of sessions, depending on the
pretransplant titer [47]. Several investigators suggested that
the decision to perform posttransplant plasmapheresis should
be based on the pretransplant anti-ABO antibody titer before
desensitization [48,49]. Others suggested that posttransplant
plasmapheresis depended on an elevation of the posttrans-
plant antibody titer [50]. Although there are no established
criteria for performing posttransplant antibody depletion,
many centers apply it to patients with a high risk for AMR,
e.g., patients with a high initial titer (41:256), a rapidly
increasing posttransplant titer (Z8-fold), or a high posttrans-
plant titer (Z1:64).
B-cell depletion
To avoid the reappearance of anti-ABO antibodies and the
associated risk of AMR, B-cell depletion is important. Old
protocols for ABOi KT included splenectomy to eliminate
B-cell pools. The principle of splenectomy was to remove a
major reservoir of lymphocytes, including antibody-secreting
B cells, B-cell precursors, and plasma cells. However, the
effect of splenectomy on the immune system is permanent
and increases the risk of infection in ABOi KT.
After some studies reported that treating ABOi KT patients
with rituximab had a long-acting B cell-depleting effect with-
out any serious side effects, splenectomy was largely replaced
by rituximab [7,10,51]. Rituximab is an anti-CD20 monoclonal
antibody that binds to CD20 on immature and mature B cells,
inducing apoptosis through antibody-dependent cellular
cytotoxicity, complement-dependent cytotoxicity, or direct
apoptosis mechanisms. However, rituximab cannot induce
apoptosis of some memory B or plasma cells. B-cell depletion
with rituximab may prevent the development of mature B
cells into antibody-producing plasma cells, reduce alloreactive
antibody production, and attenuate T-cell responses by
reducing B-cell antigen presentation and costimulation [52].
Although bortezomib, a proteasome inhibitor, is effective in
controlling plasma cells, it does not suppress either B-1 or B-2
cells [20]. Rituximab may affect macrophages and natural
killer cells through binding to the Fc receptor. B-cell depletion
by rituximab occurs at 1–3 days after administration and
persists for up to 2 years [53]. The timing and dosage of
rituximab remain variable. Because an interval is needed to
deplete antibody-producing cells, it is better to administer
rituximab at least 1 week before KT [54]. Recently, some
investigators introduced an ABOi KT protocol without rituximab,
or with only a low dose (o375 mg/m2), to avoid overimmuno-
suppression [55–58].
Intravenous immunoglobulin
Intravenous Ig (IVIG) is widely used in KT to suppress both
cell-mediated rejection and AMR, although the mechanism of
action remains unclear. Potential modes of action include
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inhibition of complement activation, neutralization of proin-
ﬂammatory cytokines, and induction of anti-inﬂammatory
cytokines [59]. IVIG is usually administered after plasmapher-
esis to reconstitute the natural levels of IgG. However, there is
no uniform dose of IVIG used in the desensitization protocol of
ABOi KT.
Maintenance immunosuppression
Maintenance immunosuppressive regimens included calci-
neurin inhibitors (CNI), antimetabolites (i.e., MMF), and steroids.
In ABOi KT protocols, tacrolimus is the CNI of choice. In
addition, stronger induction agents, such as antithymocyte
globulin (ATG), are often used for induction to suppress T cells'
help to B cells. B-1 cells are susceptible to CNI and antimeta-
bolites, whereas B-2 cells are resistant to CNI. A comparative
study showed that a 7-day regimen was more effective than a
2-day regimen as pretransplant immunosuppression [60].
Thus, maintenance immunosuppression should start 7–14
days before KT to adequately inhibit antibody production.
However, a 2-day regimen of tacrolimus (0.1 mg/kg) in ABOi KT
achieved similar outcomes to ABOc KT [56]. The effects of
CNI-sparing strategies or long-term steroids in ABOi KT remain
unclear [61,62].Current desensitization protocol of ABOi KT
With increasing experience over the last decade, desensiti-
zation protocols were modiﬁed and continue to evolve (Fig. 1)
[22,30,53,63–65]. However, the lack of controlled studies
makes it difﬁcult to compare various protocols and determine
which is best.
Most transplants in Japan are desensitized by DFPP, and
splenectomy has been replaced by rituximab. In addition, most
centers in Japan do not use IVIG. The target titers of anti-ABO
antibodies immediately before KT in Japan are usually 1:16 to
1:32 or less [22,64], even though high target titers up to 1:32
were associated with a high rate of acute AMR (33%) in the
prerituximab era [22].
In Europe, IA is widely practiced in desensitization of ABOi
KT. After Alexandre et al [3] began using ABOi KT in the 1980s, it
took 20 years until this procedure was widely used throughout
Europe. In 2003, it was reported that successful ABOi KT could
be achieved using antigen-speciﬁc IA and rituximab without
splenectomy [7]. To date, this protocol has led to successful
ABOi KTs with more than 1,000 transplants in Europe. The basis
of the North European protocol is IA followed by high-dose
IVIG. However, posttransplant IA is not performed routinely,
and its use is determined by antibody titer [50]. The target titer
of anti-ABO antibodies immediately before KT was 1:4 or less in
the Stockholm and Freiburg groups [53,63]. Although this strict
target titer can be helpful for good posttransplant outcomes,
14–21% of patients failed to satisfy this criterion [63]. In the
United States, desensitization protocols consist of classical
plasmapheresis, low-dose IVIG, and rituximab [37,65]. Some
centers use a rituximab-free protocol [65]. Target titers are 1:8
to 1:16 [30,65]. A recent report from Australia suggests that
ABOi KT can be performed without B-cell depletion procedures
such as splenectomy or rituximab [56].
In Korea, the desensitization protocols of ABOi KT are
highly uniform with routine plasmapheresis, rituximab, andtacrolimus-based maintenance immunosuppression [13]. The
timing and dosage of rituximab vary depending on the center.
Most centers use a single dose of 375 mg/m2 at the initiation
of the protocol, although the dose tends to be reduced to
200 mg/person or 100 mg/m2. Pretransplant conventional plas-
mapheresis is used in most centers, although DFPP is also used at
times. Posttransplant plasmapheresis is performed in selected
recipients with a high risk for AMR, and IVIG (100 mg/kg or
200 mg/kg) is administered after plasmapheresis in most centers.
The desensitization protocol in Seoul National University
Hospital consists of rituximab, plasmapheresis, low-dose IVIG,
and tacrolimus-based maintenance immunosuppressants
(Fig. 1F). Recipients with anti-ABO antibody titers less than
or equal to 1:512 are acceptable for ABOi KT, although patients
with a higher titer can be eligible according to the individual
situation. Rituximab administration without plasmapheresis
is applied to patients with a very low titer (r1:8). Other
recipients received DFPP and conventional plasmapheresis
at a ratio of 2:1, for three to 12 sessions before KT, with a
target titer of 1:16 or less, because a target titer higher than
1:16 is associated with an increased risk for acute AMR [22].
Low-dose IVIG (100 mg/kg) is administered after plasmapher-
esis. A single dose of rituximab (150 mg/m2) was administered
1 week before plasmapheresis to minimize removal of
rituximab. Plasmapheresis with FFP is performed on the last
session before KT. Tacrolimus-based immunosuppression is
initiated 1 week or 2 weeks before KT and combined with two
doses of basiliximab. The target trough level of tacrolimus was
8–10 ng/mL, and MMF was administered at a dose of 1.0 g/d in
most patients. In the presence of high anti-ABO antibody
levels (Z1:256 before KT, Z1:64 after KT), plasmapheresis
and low-dose IVIG are recommended during the posttrans-
plant period.Treatment of AMR
Standard treatment for AMR consists of plasmapheresis or
IA and IVIG [66]. Most centers treat AMR with a series of
plasma exchanges followed by low-dose IVIG in addition to
methylprednisolone, until clinical improvement or histologic
resolution of AMR is achieved [30,67,68]. Although reversal
rates for AMR using this protocol were better than reversal
rates with traditional immunosuppression alone [31], data
about reversal rates for AMR in ABOi KT are rare and compli-
cated by the concomitant presence of DSA. Rituximab is an
efﬁcient agent to treat AMR by depleting B cells and thereby
controlling DSA production [69]. Some studies suggest that
rituximab is the treatment of choice in AMR [70,71]. ATG, at
the time of plasmapheresis, is also often administered to treat
AMR [22,66].
New drugs have been introduced for the treatment of AMR
because plasmapheresis, IVIG, ATG, and rituximab can have
suboptimal results because of poor direct effects on mature
plasma cells [72]. Bortezomib is effective in the treatment of
refractory AMR due to anti-HLA DSA by inducing plasma cell
apoptosis [72,73]. However, the ability of bortezomib to affect
anti-ABO antibodies is controversial [74,75]. Eculizumab, a
humanized monoclonal antibody against complement protein
C5, prevents the cleavage of C5 to C5a and C5b, subsequently
preventing the generation of the C5b-C9 membrane attack
complex. Recent reports indicate that eculizumab is useful in
the treatment of AMR [66,76,77].
Figure 1. Desensitization protocols for ABOi KT.* This ﬁgure shows representative desensitization protocols for ABOi KT used at several transplant
centers. Most centers have modiﬁed the original successful protocol. Desensitization protocols of Tokyo Women’s Medial University, Japan (A), Freiburg
University Hospital, Germany (B), Stockholm group, Sweden (C), Johns Hopkins Hospital, USA (D), Mayo Clinic, USA (E), and Seoul National University
Hospital, Korea (F), are shown. Details of the desensitization protocols of several centers can be found in the references [22,30,53,63–65].
ABOi KT, ABO incompatible kidney transplantation; Anti-IL-2R, anti-interleukin-2 antibody; ATG, antithymocyte globulin; DFPP, double ﬁltration
plasmapheresis; IVIG, intravenous immunoglobulin; OP, transplantation operation; PP, plasmapheresis; RTX, rituximab.
*These ﬁgures are based on published data of current protocols for an individual center. These protocols may have changed since publication.
Kidney Res Clin Pract 34 (2015) 170–179174Outcomes of ABOi KT
Patient and graft survival
Short-term patient and graft survival in ABOi KT are notable
in most published data [3,4,11,22,53,56,57,67,78–84]. Long-
term outcomes of ABOi KT reported by most centers are
comparable with ABOc KT [11,64].
Outcomes of a large number of Japanese ABOi KTs, with
follow-up periods of more than 20 years, are reported [4]. In
addition, outcomes for earlier (1989–2000) and recent eras
(2001–2010) were compared. The patient and graft survival
rates during the earlier era were 84% and 58% at 9 years,
respectively. During the recent era, the patient and graft
survival rates were 91% and 83% for 9 years, respectively.
These data showed that both patient and graft survival
signiﬁcantly improved in the recent era. This is due to main-
tenance immunosuppression based on tacrolimus and MMF
and the use of rituximab. Takahashi et al [64] investigated the
comparison of graft survival between 441 ABOi KT patientsand 41,000 ABOc KT patients. The graft survival tended to be
lower in ABOi KT group after 1 year, but this difference was not
signiﬁcant after 5 years and 10 years.
Data from the Scientiﬁc Registry of Transplant Recipients on
the outcomes of 738 ABOi KTs that were performed between
1995 and 2010 have been reported [11]. Comparing ABOi KT
cases with 43,000 ABOc KT cases, the 1-year graft survival
was 94.1% in ABOi KT versus a slightly higher 97.1% in ABOc KT.
However, there was no difference in the 10-year graft survival
[11]. The Collaborative Transplant Study reported outcomes
from 1,420 ABOi KTs performed at 101 transplants centers
from 2005 to 2012 [84]. Three-year graft survival rates of ABOi
KT were not different from those of the matched ABOc KT
(89.9% vs. 90.1%). Although patient survival rates in the early
period were lower in ABOi KT because of a higher rate of death
from infection, 3-year patient survival rates were similar
(95.6% vs. ABOc, 96.3%). Antibody reduction with IA resulted
in a similar rate of graft survival compared with reduction with
plasmapheresis. Kong et al [13] analyzed 125 ABOi KTs that
were performed from 2007 to 2010 in Korea. Two-year graft
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These data indicate similar survival outcomes after ABOi and
ABOc KT.
Acute AMR and T cell-mediated rejection in ABOi KT
Protocol biopsy specimens at 3 months after ABOi KT
showed a signiﬁcantly higher incidence of AMR compared
with ABOc KT (18% vs. 1%) [85], indicating an increased risk for
acute AMR in ABOi KT due to anti-ABO antibodies. However,
there was no signiﬁcant difference in the incidence of acute
T cell-mediated rejection between ABOi KT and ABOc KT (48.4%
vs. 35.7%). Gloor et al [86] analyzed 1-year protocol biopsy
specimens and found that there was a signiﬁcant difference in
the rate of AMR between ABOi KT and ABOc KT without HLA
antibodies. Setoguchi et al [33] also showed that ABOi allografts
had a higher overall incidence of AMR compared with ABOc
allografts (27% vs. 5.3%). AMR was detected in 15% of ABOi KT at
1 month and 30% at 6–12 months, compared with 35% at
1 month and 11% at 6–12 months in ABOc KT. However, recent
studies using rituximab reported improved outcomes of ABOi KT
and demonstrated that acute AMR rates were similar between
ABOi KT and ABOc KT [8,87]. Acute AMR rates during the ﬁrst
5 years were 4.0% and 2.5% in ABOi and ABOc KT, respectively.
Five-year rates of acute T cell-mediated rejection were 4.0% and
14.3% in ABOi and ABOc KT, respectively [8]. Acute AMR rates in
6-month and 2-year biopsy samples were 3.5% and 0.0% in
ABOi KT and 10.8% and 2.4% in ABOc KT, respectively [87]. We
should consider that anti-HLA DSA could be a main pathogenic
factor, rather than anti-ABO antibodies, in acute AMR after
ABOi KT [22].
Chronic rejection
The National Institutes of Health suggested diagnostic
criteria for chronic AMR in ABOi KT [31]. Speciﬁcally, at least
three of the following four lesions could be present: arterial
intimal ﬁbrosis, interstitial ﬁbrosis/tubular atrophy, duplica-
tion of the glomerular basement membrane, or lamination of
the peritubular capillary basement membrane.
AMR in the early posttransplant period has adverse impacts
on long-term graft survival and contributes to chronic rejec-
tion [34]. Several studies show that a history of AMR is
signiﬁcantly associated with the development of transplant
glomerulopathy [22,37]. When chronic AMR rates were com-
pared in the rituximab era, they were signiﬁcantly lower in the
2-year biopsy sample but not the 6-month biopsy sample from
ABOi KT compared with ABOc KT (1.8% and 3.5% in ABOi KT
and 0.0% and 28.9% in ABOc KT, at 6 months and 2 years,
respectively) [87]. Furthermore, formation of de novo DSA and
DSA-related chronic AMR occurred less in ABOi KT because of
desensitization effects [87].
Adverse effects of ABOi KT
The literature on infectious complications after ABOi KT is
controversial. Genberg et al [53] reported no statistical differ-
ence in infectious complications between ABOi KT and ABOc
KT. Later, Habicht et al [81] reported that the infection rate in
ABOi KT was signiﬁcantly higher than that in ABOc KT (60% vs.
30%). Viral infections, including with cytomegalovirus, herpes
simplex virus, varicella-zoster virus, and BK virus, showed a
higher incidence in ABOi KT compared with ABOc KT.B-cell depletion by rituximab may be associated with an
increased risk of infection in ABOi KT. Grim et al [88] reported
that the incidence of posttransplant infection in HLA-
sensitized KT or ABOi KT treated with rituximab (48%) was
greater than in HLA-sensitized KT without rituximab (11%).
Kamar et al [89] showed that the infection rate in KT
was similar with and without rituximab (45.5% vs. 53.9%).
However, infection-associated mortality was signiﬁcantly
higher in the rituximab group. Therefore, treatment with
sulfamethoxazole/trimethoprim or acyclovir is recommended
to prevent relatively common Pneumocystis jiroveci or viral
infections in ABOi KT.
Although immunosuppression in KT is associated with an
increased incidence of malignancy compared with the general
population [90], when Yamamoto et al [91] retrospectively
analyzed the malignancy risk of ABOi KT compared with ABOc
KT, there was no signiﬁcant difference (4.8% vs. 4.2%). Simi-
larly, Hall et al [92] showed that the incidence of malignancy
in ABOi KT was similar to that in matched ABOc KT. Further
analyses with long-term follow-up are needed to adequately
assess the risk of malignancy in ABOi KT.Cost of ABO incompatible KT
Although KT is a cost-effective modality over dialysis
[93,94], ABOi KT is more expensive than ABOc KT because of
desensitization procedures. The cost of ABOi KT in the ﬁrst 90
days after transplantation is $90,300 compared to $52,500 for
ABOc KT in the U.S.A. However, ABOi KT is cost-effective
compared to maintenance dialysis while waiting for ABOc
KT, because ABOi KT saves $130,000 for 5 years compared to
dialysis [95]. Cost of ABOi KT based on immunoadsorption is
higher than that based on plasmapheresis, while it is still cost-
effective compared to dialysis [96].Unresolved issues in ABOi KT
Acceptable titer of anti-ABO antibodies before and after KT
The prognostic value of a baseline anti-ABO titer is con-
troversial. A high baseline titer is associated with higher failure
rate to reach the target titer immediately before KT [97,98] and
was also associated with AMR, severity of AMR, and graft
failure [2,9,99,100]. However, several studies reported that a
high baseline titer is not a predictor of poor allograft outcomes
in recipients treated with tacrolimus or MMF immunosup-
pressive regimens [22,37]. The lack of well-controlled com-
parative studies and variable study designs make it difﬁcult to
resolve this issue. Nevertheless, a high baseline titer itself is
not an absolute contraindication to ABOi KT but should be
managed very carefully as a risk factor for failing to reach the
target titer and development of acute AMR.
The anti-ABO antibody titer before KT should be low, but the
acceptable upper limit is based on empirical evidence. Accep-
table titers of anti-ABO antibodies at the time of transplantation
have varied between 1:4 and 1:32 according to the protocol of
individual centers [53,55–57,65,67,78,79,81–83]. Therefore, the
optimal titer should be determined according to the pretrans-
plant and posttransplant immunosuppressive protocols.
Some centers recommend that the anti-ABO antibody titer
should be low (1:8 to 1:16) during the early posttransplant period
Kidney Res Clin Pract 34 (2015) 170–179176[9,30,101]. Other studies demonstrated that the clinical signiﬁ-
cance of an increased anti-ABO antibody titer during the post-
transplant period is variable and that there was no signiﬁcant
correlation with AMR [1,2,102]. A high antibody titer may be
necessary but is not sufﬁcient for AMR. Overall, these ﬁndings
indicate that the titer should be monitored for at least 3 weeks
after ABOi KT, and high posttransplant titers (Z1:64) that are
associated with a high risk for acute AMR should be treated [2,22].Necessity of rituximab and IVIG
The necessity and optimal dosage of rituximab remain
unclear, although most centers use low doses for desensitization
in ABOi KT. Despite good short-term effects of low-dose ritux-
imab, long-term controlled studies are needed to determine
their value. The empirical use of postpheresis replacement of
IVIG is common, but its necessity has also not been conﬁrmed
experimentally.Minimizing immunosuppression
Various groups have attempted to minimize immunosup-
pression to reduce the long-term risk of overimmunosuppres-
sion in ABOi KT [36,103]. Magee et al [36] suggested avoiding
lymphocyte-depleting antibodies because they were not effec-
tive for preventing AMR and were associated with a higher
incidence of infection. Tacrolimus has contributed to success-
ful outcomes of ABOi KT in the modern era. However, Chuang
et al [103] reported that there was no signiﬁcant difference in
the isoagglutinin titer between tacrolimus and cyclosporine
groups. Two studies analyzed the effect of steroid withdrawal
1–2 weeks after ABOi KT [67,104]. One study reported success-
ful withdrawal in 44% of recipients, but with 30% biopsy-
proven acute rejection within 1 year [104]. Another study
analyzed 10 recipients, 30% with biopsy-proven acute rejection
[67]. Oettl et al [78] analyzed 11 ABOi KT recipients with late
steroid withdrawal. Biopsy-proven acute rejection occurred in
55% during or soon after steroid cessation [62]. Based on these
data, steroid withdrawal in ABOi KT is not recommended or
should only be performed after a protocol biopsy showing
normal histologic ﬁndings. There should also be clinical, and in
doubtful cases, a histologic follow-up [105]. Overall, the avail-
able evidence is not sufﬁcient to minimize maintenance
immunosuppression in ABOi KT.Conclusion
Thanks to advances in our understanding of immunopatho-
genesis and immune-modulating techniques during the last 10
years, ABOi KT now has outcomes comparable with ABOc KT in
both efﬁcacy and safety. ABOi KT is thus an important step
forward in expanding the kidney donor pool. Additional
studies are needed to clarify optimal pretransplant desensiti-
zation regimens, mechanisms of accommodation, and the best
treatment protocol for acute and chronic AMR after ABOi KT.Conﬂicts of interest
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